Boston Scientific Q4 revenue slightly beats expectations

Overview

• Medical technology firm's Q4 revenue slightly beat analyst expectations

• Adjusted EPS for Q4 beat analyst expectations

• Company initiated U.S. launch of SEISMIQ IVL System for peripheral artery disease

Outlook

• Boston Scientific estimates full-year 2026 net sales growth of 10.5% to 11.5%

• Company expects first-quarter 2026 adjusted EPS between $0.78 and $0.80

• Boston Scientific forecasts organic sales growth of 10.0% to 11.0% for 2026

Result Drivers

• CARDIOVASCULAR GROWTH - Cardiovascular segment reported 18.2% sales growth, contributing significantly to overall revenue increase

• REGIONAL SALES - U.S. sales grew 17%, leading regional performance, followed by strong growth in APAC and Emerging Markets

• PRODUCT DISCONTINUATION - Discontinued sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems, impacting sales figures

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 34 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Boston Scientific Corp is $124.50, about 35.9% above its February 3 closing price of $91.62

• The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release: ID:nPn2qBB38a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.